Análisis de la acción LeMaitre Vascular Inc (LMAT)LMATLeMaitre Vascular Inc

LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. It develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which are used in open vascular surgery and dialysis access. It offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold globally in the United States, Europe, Canada and Asia Pacific. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

LeMaitre Vascular Inc is currently not a strong buy due to recent performance metrics and analyst sentiments. The current price is $80.45, with a recent RSI of 40.28 indicating a potential oversold condition, but the stock has seen a 20.60% decline over the last 20 days, which raises concerns. Additionally, hedge funds are selling, with a 398.42% increase in selling activity over the last quarter, suggesting caution. The main risk is the recent earnings miss, with reported EPS at $0.74 versus an estimate of $0.81, leading to a 25.32% drop in share price post-earnings.

8 analysts cover LMAT: 2 rate it Buy, 6 Hold and 0 Sell. The average price target is 105.20.